Lifecore Biomedical, Inc. (LFCR)
USD 5.81
(1.57%)
USD 5.81
(1.57%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 120.51 Million USD | 19.24% |
| 2023 | 110.98 Million USD | 3.27% |
| 2022 | 107.46 Million USD | -42.99% |
| 2021 | 188.51 Million USD | 47.57% |
| 2020 | 127.74 Million USD | 40.8% |
| 2019 | 90.72 Million USD | 121.28% |
| 2018 | 41 Million USD | -10.93% |
| 2017 | 46.03 Million USD | -8.7% |
| 2016 | 50.41 Million USD | 47.57% |
| 2015 | 34.16 Million USD | 20.66% |
| 2014 | 28.31 Million USD | -17.62% |
| 2013 | 34.37 Million USD | -14.72% |
| 2012 | 40.3 Million USD | 160.03% |
| 2011 | 15.5 Million USD | -19.48% |
| 2010 | 19.24 Million USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 2.54 Million USD | 16.84% |
| 2004 | 2.17 Million USD | -43.9% |
| 2003 | 3.87 Million USD | -26.22% |
| 2002 | 5.25 Million USD | -59.08% |
| 2001 | 12.83 Million USD | -22.82% |
| 2000 | 16.63 Million USD | 539.65% |
| 1999 | 2.6 Million USD | -3.7% |
| 1998 | 2.7 Million USD | 0.0% |
| 1997 | - USD | -100.0% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 FY | 120.51 Million USD | 8.59% |
| 2024 Q2 | 108.96 Million USD | 1.69% |
| 2024 Q4 | 120.51 Million USD | 3.67% |
| 2024 Q3 | 116.24 Million USD | 6.69% |
| 2024 Q1 | 107.14 Million USD | 6.02% |
| 2023 Q4 | 110.98 Million USD | -11.55% |
| 2023 FY | 110.98 Million USD | 3.27% |
| 2023 Q1 | 105.31 Million USD | 954.91% |
| 2023 Q2 | 8.99 Million USD | -91.45% |
| 2023 Q3 | 125.48 Million USD | 1294.38% |
| 2022 Q1 | 140.9 Million USD | -25.25% |
| 2022 Q3 | 89.94 Million USD | -35.01% |
| 2022 Q4 | 9.98 Million USD | -88.9% |
| 2022 Q2 | 138.39 Million USD | -1.78% |
| 2022 FY | 107.46 Million USD | -42.99% |
| 2021 Q3 | 169.48 Million USD | 62.64% |
| 2021 FY | 188.51 Million USD | 47.57% |
| 2021 Q1 | 116.93 Million USD | -8.46% |
| 2021 Q2 | 104.2 Million USD | -10.89% |
| 2021 Q4 | 188.51 Million USD | 11.23% |
| 2020 Q2 | 138.26 Million USD | 20.47% |
| 2020 FY | 127.74 Million USD | 40.8% |
| 2020 Q4 | 127.74 Million USD | -2.71% |
| 2020 Q3 | 131.29 Million USD | -5.04% |
| 2020 Q1 | 114.77 Million USD | 26.51% |
| 2019 FY | 90.72 Million USD | 121.28% |
| 2019 Q1 | 39.74 Million USD | -3.08% |
| 2019 Q2 | 38.47 Million USD | -3.18% |
| 2019 Q4 | 90.72 Million USD | -2.65% |
| 2019 Q3 | 93.19 Million USD | 142.21% |
| 2018 Q2 | 43.51 Million USD | -2.81% |
| 2018 Q1 | 44.77 Million USD | -2.73% |
| 2018 Q4 | 41 Million USD | -2.98% |
| 2018 FY | 41 Million USD | -10.93% |
| 2018 Q3 | 42.26 Million USD | -2.89% |
| 2017 Q2 | 48.54 Million USD | 1.44% |
| 2017 Q1 | 47.85 Million USD | -5.09% |
| 2017 Q4 | 46.03 Million USD | -2.65% |
| 2017 FY | 46.03 Million USD | -8.7% |
| 2017 Q3 | 47.28 Million USD | -2.59% |
| 2016 FY | 50.41 Million USD | 47.57% |
| 2016 Q2 | 34.68 Million USD | 5.26% |
| 2016 Q1 | 32.95 Million USD | -3.55% |
| 2016 Q3 | 52.31 Million USD | 50.84% |
| 2016 Q4 | 50.41 Million USD | -3.63% |
| 2015 Q1 | 33.05 Million USD | 16.72% |
| 2015 Q4 | 34.16 Million USD | 3.84% |
| 2015 Q2 | 34.67 Million USD | 4.91% |
| 2015 FY | 34.16 Million USD | 20.66% |
| 2015 Q3 | 32.9 Million USD | -5.12% |
| 2014 Q4 | 28.31 Million USD | -4.86% |
| 2014 Q3 | 29.76 Million USD | -4.57% |
| 2014 FY | 28.31 Million USD | -17.62% |
| 2014 Q2 | 31.18 Million USD | -5.38% |
| 2014 Q1 | 32.96 Million USD | -4.11% |
| 2013 Q3 | 35.79 Million USD | -3.76% |
| 2013 Q2 | 37.19 Million USD | -4.48% |
| 2013 Q1 | 38.93 Million USD | -3.4% |
| 2013 FY | 34.37 Million USD | -14.72% |
| 2013 Q4 | 34.37 Million USD | -3.97% |
| 2012 Q1 | 14.5 Million USD | -6.45% |
| 2012 Q3 | 12.17 Million USD | -7.59% |
| 2012 Q4 | 40.3 Million USD | 231.18% |
| 2012 FY | 40.3 Million USD | 160.03% |
| 2012 Q2 | 13.17 Million USD | -9.17% |
| 2011 Q2 | 17.5 Million USD | -7.04% |
| 2011 Q3 | 16.5 Million USD | -5.71% |
| 2011 FY | 15.5 Million USD | -19.48% |
| 2011 Q4 | 15.5 Million USD | -6.07% |
| 2011 Q1 | 18.82 Million USD | -2.2% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | 19.24 Million USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | 19.24 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | 76 Thousand USD | 0.0% |
| 2008 Q2 | 76 Thousand USD | 0.0% |
| 2008 Q4 | - USD | -100.0% |
| 2008 Q3 | 76 Thousand USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q3 | 1.94 Million USD | 0.1% |
| 2006 Q2 | 1.94 Million USD | -1.57% |
| 2006 FY | - USD | -100.0% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q1 | 1.97 Million USD | -22.13% |
| 2005 Q1 | 2.1 Million USD | -3.08% |
| 2005 FY | 2.54 Million USD | 16.84% |
| 2005 Q4 | 2.54 Million USD | -4.9% |
| 2005 Q3 | 2.67 Million USD | -4.81% |
| 2005 Q2 | 2.8 Million USD | 33.18% |
| 2004 Q1 | 3.53 Million USD | -7.46% |
| 2004 FY | 2.17 Million USD | -43.9% |
| 2004 Q3 | 2.26 Million USD | -30.11% |
| 2004 Q2 | 3.23 Million USD | -8.43% |
| 2004 Q4 | 2.17 Million USD | -3.85% |
| 2003 Q4 | 3.81 Million USD | -2.65% |
| 2003 FY | 3.87 Million USD | -26.22% |
| 2003 Q3 | 3.92 Million USD | -25.32% |
| 2003 Q2 | 5.25 Million USD | -43.82% |
| 2003 Q1 | 9.34 Million USD | -8.94% |
| 2002 FY | 5.25 Million USD | -59.08% |
| 2002 Q2 | 12.83 Million USD | -16.3% |
| 2002 Q3 | 11.32 Million USD | -11.78% |
| 2002 Q1 | 15.33 Million USD | 5.06% |
| 2002 Q4 | 10.26 Million USD | -9.33% |
| 2001 Q1 | 17.36 Million USD | -8.52% |
| 2001 FY | 12.83 Million USD | -22.82% |
| 2001 Q4 | 14.59 Million USD | -4.61% |
| 2001 Q2 | 16.63 Million USD | -4.2% |
| 2001 Q3 | 15.3 Million USD | -7.99% |
| 2000 Q1 | 2.6 Million USD | -3.7% |
| 2000 FY | 16.63 Million USD | 539.65% |
| 2000 Q3 | 18.8 Million USD | 623.08% |
| 2000 Q2 | 2.6 Million USD | 0.0% |
| 2000 Q4 | 18.97 Million USD | 0.94% |
| 1999 Q3 | 2.7 Million USD | 0.0% |
| 1999 Q4 | 2.7 Million USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | 2.7 Million USD | 0.0% |
| 1999 FY | 2.6 Million USD | -3.7% |
| 1998 Q2 | - USD | -100.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | 2.7 Million USD | 0.0% |
| 1998 Q1 | 100 Thousand USD | -50.0% |
| 1997 Q3 | 300 Thousand USD | 0.0% |
| 1997 Q1 | 400 Thousand USD | 0.0% |
| 1997 Q2 | 300 Thousand USD | -25.0% |
| 1997 Q4 | 200 Thousand USD | -33.33% |
| 1997 FY | - USD | -100.0% |
| 1996 Q4 | 400 Thousand USD | 0.0% |
| 1996 FY | 300 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bright Green Corporation | 201.78 Thousand USD | -59622.573% |
| Alpha Teknova, Inc. | 13.25 Million USD | -809.441% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 61.084% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -32.318% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 75.404% |
| Cosmos Health Inc. | 3.03 Million USD | -3870.229% |
| Journey Medical Corporation | 14.62 Million USD | -724.169% |
| Embecta Corp. | 1.62 Billion USD | 92.586% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 75.972% |
| Dynavax Technologies Corporation | 252.41 Million USD | 52.258% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -804.322% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 76.545% |
| PainReform Ltd. | 30 Thousand USD | -401600.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -22256.619% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -22256.619% |
| SCYNEXIS, Inc. | 12.15 Million USD | -891.118% |
| Safety Shot Inc | 304.9 Thousand USD | -39423.527% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -102786.561% |
| Procaps Group, S.A. | 28.41 Million USD | -324.182% |
| Theratechnologies Inc. | 51.26 Million USD | -135.091% |
| Harrow Health, Inc. | 183.17 Million USD | 34.209% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -138417.241% |
| Biofrontera Inc. | 804 Thousand USD | -14888.806% |
| DURECT Corporation | 2.7 Million USD | -4360.03% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -263.026% |
| Cronos Group Inc. | 1.55 Million USD | -7629.955% |
| OptiNose, Inc. | 611 Thousand USD | -19623.404% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 75.816% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -252.471% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -26385.714% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -98.387% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -842.652% |
| Radius Health, Inc. | 339.66 Million USD | 64.521% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -1074.79% |
| Phibro Animal Health Corporation | 458.28 Million USD | 73.704% |
| Procaps Group S.A. | 28.41 Million USD | -324.182% |
| Alvotech | 1.02 Billion USD | 88.275% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -1744.917% |
| Viatris Inc. | 16.18 Billion USD | 99.256% |
| Rockwell Medical, Inc. | 8.29 Million USD | -1353.153% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -1007.934% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -35767.032% |
| Tilray Brands, Inc. | 287.93 Million USD | 58.147% |
| Shineco, Inc. | 10.01 Million USD | -1103.015% |
| PetIQ, Inc. | 437.82 Million USD | 72.475% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -57285.714% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 53.345% |
| Alimera Sciences, Inc. | 64.48 Million USD | -86.869% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -212.899% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -89107.856% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -1657.381% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -16637.5% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -535881.142% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -267.857% |
| Hempacco Co., Inc. | 5.93 Million USD | -1931.866% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 88.275% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -114.37% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 80.441% |
| Currenc Group, Inc. | 2.5 Million USD | -4706.99% |
| Kamada Ltd. | 7.43 Million USD | -1520.194% |
| Indivior PLC | 235.66 Million USD | 48.864% |
| Evoke Pharma, Inc. | 5 Million USD | -2310.2% |
| Flora Growth Corp. | 942 Thousand USD | -12692.994% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -535881.142% |
| Evolus, Inc. | 120.35 Million USD | -0.125% |
| HUTCHMED (China) Limited | 48.18 Million USD | -150.078% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 79.547% |
| Akanda Corp. | 2.49 Million USD | -4725.892% |